Table 2.
Use of ADV in treatment of recurrent graft infection after LT
| Author (Ref.) | n |
Pre-treatment |
Treatment duration (mo), mean (range) | ADV dosage (mg/d) | ConcurrentLAM use |
Post-treatment |
||||
| HBV DNA+ (%) | HBeAg+ (%) | HBV DNA negative following treatment (%) | HBsAg seroconversion (%) | ALT normalization (%) | Development of ADV mutants | |||||
| Akyildiz et al[44] | 11 | 81.8 | 9.1 | 18 (6-48) | 10 | Yes | 77.8 | 11.1 | 81.8 | None |
| Limquiaco et al[45] | 7 | 100 | 71.4 | 35 (22-48) | 10 | Yes | 28.6 | 20 | 86 | None |
| Bárcena et al[46] | 42 | 100 | 71.4 | 21.5 (12-31) | 10 | No | 64 | 20 | 70.5 | None |
| Herreros de Tejada Echanojáuregui et al[47] | 7 | 100 | 71.4 | 11 | 10 | Yes1 | 42.9 | 20 | NA | None |
| Neff et al[48] | 9 | 100 | 77.8 | 30 (6-48) | 10 | No | 0 | 57.1 | NA | None |
1
LAM was changed to ADV in 5 patients and ADV was added to LAM in the other 2 patients. ADV: Adefovir dipivoxil.